Daniel E. Stepan

3.9k total citations · 4 hit papers
35 papers, 2.8k citations indexed

About

Daniel E. Stepan is a scholar working on Molecular Biology, Oncology and Reproductive Medicine. According to data from OpenAlex, Daniel E. Stepan has authored 35 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Oncology and 9 papers in Reproductive Medicine. Recurrent topics in Daniel E. Stepan's work include Cancer Immunotherapy and Biomarkers (9 papers), Ovarian cancer diagnosis and treatment (8 papers) and Renal cell carcinoma treatment (6 papers). Daniel E. Stepan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Ovarian cancer diagnosis and treatment (8 papers) and Renal cell carcinoma treatment (6 papers). Daniel E. Stepan collaborates with scholars based in United States, France and Spain. Daniel E. Stepan's co-authors include Matthew H. Taylor, Corina E. Dutcus, Vicky Makker, Robert Shumaker, Drew Rasco, Yu-Nien Sun, Emmett V. Schmidt, Jane Wu, Lori J. Wirth and Lars Bastholt and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Daniel E. Stepan

34 papers receiving 2.8k citations

Hit Papers

Micafungin versus Flucona... 2004 2026 2011 2018 2004 2019 2020 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation
    2004 526 citations V. Ratanatharathorn, Daniel E. Stepan et al. Clinical Infectious Diseases profile →
  2. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    2019 360 citations Vicky Makker, Drew Rasco et al. The Lancet Oncology profile →
  3. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
    2020 359 citations Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology profile →
  4. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
    2020 306 citations Matthew H. Taylor, Chung‐Han Lee et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Daniel E. Stepan 1.3k 636 627 538 531 35 2.8k
Claire W. Michael 511 0.4× 403 0.6× 846 1.3× 559 1.0× 464 0.9× 105 2.5k
Mohammed Akhtar 631 0.5× 241 0.4× 1.7k 2.7× 1.3k 2.5× 125 0.2× 134 3.1k
José Miguel Esteban López-Jamar 1.1k 0.8× 348 0.5× 797 1.3× 976 1.8× 64 0.1× 95 3.5k
Catherine Lhommé 949 0.7× 341 0.5× 478 0.8× 1.3k 2.4× 63 0.1× 119 4.2k
Harry J. Long 1.7k 1.3× 1.1k 1.7× 674 1.1× 915 1.7× 37 0.1× 95 4.8k
Khush Mittal 491 0.4× 328 0.5× 359 0.6× 545 1.0× 52 0.1× 73 3.1k
Vincent Molinié 609 0.5× 458 0.7× 2.3k 3.7× 1.9k 3.6× 171 0.3× 166 4.1k
Kuniyuki Oka 629 0.5× 343 0.5× 405 0.6× 413 0.8× 30 0.1× 101 1.8k
Nicole Massoll 356 0.3× 275 0.4× 247 0.4× 510 0.9× 581 1.1× 41 1.7k
Semra Paydaş 1.0k 0.8× 274 0.4× 391 0.6× 627 1.2× 20 0.0× 208 2.7k

Countries citing papers authored by Daniel E. Stepan

Since Specialization
Citations

This map shows the geographic impact of Daniel E. Stepan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Stepan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Stepan more than expected).

Fields of papers citing papers by Daniel E. Stepan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Stepan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Stepan. The network helps show where Daniel E. Stepan may publish in the future.

Co-authorship network of co-authors of Daniel E. Stepan

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Stepan. A scholar is included among the top collaborators of Daniel E. Stepan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Stepan. Daniel E. Stepan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stepan, Daniel E., et al.. (2025). Coarse-grained mathematical models for studying mechanical properties of the DNA. Biophysical Reviews. 17(5). 1233–1240.
2.
Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2020). Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. Journal of Clinical Oncology. 38(26). 2981–2992. 359 indexed citations breakdown →
3.
Taylor, Matthew H., Chung‐Han Lee, Vicky Makker, et al.. (2020). Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. Journal of Clinical Oncology. 38(11). 1154–1163. 306 indexed citations breakdown →
4.
Vogelzang, Nicholas J., Marcia S. Brose, Allen Lee Cohn, et al.. (2020). Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial. Gynecologic Oncology. 159. 6–7. 2 indexed citations
5.
Makker, Vicky, Drew Rasco, Nicholas J. Vogelzang, et al.. (2019). Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology. 20(5). 711–718. 360 indexed citations breakdown →
6.
Vogelzang, Nicholas J., Carlos A. Encarnacion, Allen Lee Cohn, et al.. (2019). Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer.. Journal of Clinical Oncology. 37(8_suppl). 11–11. 9 indexed citations
7.
Brose, Marcia S., Nicholas J. Vogelzang, Christopher DiSimone, et al.. (2019). A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.. Journal of Clinical Oncology. 37(8_suppl). 16–16. 9 indexed citations
8.
Glen, Hilary, Javier Puente, Daniel Yick Chin Heng, et al.. (2018). A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg QD) in renal cell carcinoma (RCC) after 1 prior VEGF-targeted treatment.. Journal of Clinical Oncology. 36(6_suppl). TPS707–TPS707. 3 indexed citations
9.
Lee, Chi‐Hang, Vicky Makker, Matthew H. Taylor, et al.. (2017). A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma. Annals of Oncology. 28. v295–v296. 22 indexed citations
10.
Makker, Vicky, Drew Rasco, Corina E. Dutcus, et al.. (2017). A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma.. Journal of Clinical Oncology. 35(15_suppl). 5598–5598. 26 indexed citations
11.
Lü, Jianfeng, Erik Rasmussen, Beth Y. Karlan, et al.. (2011). Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemotherapy and Pharmacology. 69(5). 1135–1144. 34 indexed citations
12.
Karlan, Beth Y., Amit M. Oza, Gary Richardson, et al.. (2011). Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer. Journal of Clinical Oncology. 30(4). 362–371. 171 indexed citations
13.
Leach, Joseph W., Sidney Scudder, Charles H. Pippitt, et al.. (2010). Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer.. Journal of Clinical Oncology. 28(15_suppl). 5049–5049. 5 indexed citations
14.
Schlumberger, Martin, Rossella Elisei, Lars Bastholt, et al.. (2009). Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer. Journal of Clinical Oncology. 27(23). 3794–3801. 257 indexed citations
15.
Claret, Laurent, Jianfeng Lu, Yu Sun, Daniel E. Stepan, & René Bruno. (2009). A modeling framework to simulate motesanib efficacy in thyroid cancer. Journal of Clinical Oncology. 27(15_suppl). e14553–e14553. 1 indexed citations
16.
Sherman, Steven I., Lori J. Wirth, Jean-Pierre Droz, et al.. (2008). Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer. New England Journal of Medicine. 359(1). 31–42. 363 indexed citations
17.
Stepan, Daniel E., et al.. (2005). Safety Profile of AMG 531 in Healthy Volunteers and in Thrombocytopenic Patients with Immune Thromobocytopenic Purpura.. Blood. 106(11). 1240–1240. 6 indexed citations
18.
Ratanatharathorn, V., Daniel E. Stepan, Carole B. Miller, et al.. (2004). Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases. 39(10). 1407–1416. 526 indexed citations breakdown →
19.
20.
Smith, Eileen, Irena Sniecinski, Andrew Dagis, et al.. (1998). Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biology of Blood and Marrow Transplantation. 4(1). 27–37. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claire W. Michael Breakdown of academic impact, for papers by Mohammed Akhtar Breakdown of academic impact, for papers by José Miguel Esteban López-Jamar Breakdown of academic impact, for papers by Catherine Lhommé Breakdown of academic impact, for papers by Harry J. Long Breakdown of academic impact, for papers by Khush Mittal Breakdown of academic impact, for papers by Vincent Molinié Breakdown of academic impact, for papers by Kuniyuki Oka Breakdown of academic impact, for papers by Nicole Massoll Breakdown of academic impact, for papers by Semra Paydaş
Rankless by CCL
2026